Lexaria Bioscience Corp. (LEXX)
Bid | 0.8 |
Market Cap | 16.75M |
Revenue (ttm) | 525.92K |
Net Income (ttm) | -9.38M |
EPS (ttm) | -0.61 |
PE Ratio (ttm) | -1.41 |
Forward PE | -1.59 |
Analyst | Buy |
Ask | 0.95 |
Volume | 168,657 |
Avg. Volume (20D) | 106,485 |
Open | 0.83 |
Previous Close | 0.87 |
Day's Range | 0.83 - 0.93 |
52-Week Range | 0.83 - 4.38 |
Beta | 0.94 |
About LEXX
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for LEXX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
4 days ago · accessnewswire.com
Lexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideNew patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...

2 months ago · thenewswire.com
Lexaria Announces $2 Million Registered Direct Offering of Common StockKelowna, British Columbia – TheNewswire - April 25, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today annou...

2 months ago · accessnewswire.com
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyPfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2...